Side effects of Interferon 2b and Ribivarin
Question:
It is from the package insert: http://www.fda.gov/cber/label/pegsche080701LB.htm
Response:
1) I went through the Case Study, received 2x dose and lost 30 pounds. 2) Only got flu symptoms for 12-36 house after weekly shot. I know people getting half my dose were getting much sicker. 3) Turned out my virus was not gone,after a year. I’m off treatments, take Milk Thistle, Coliadal Silver and B Vitamins, gained back 10 pounds so far, and feel much better. 4) My liver is OK for now, but I’m hoping a newer, more effective treatment is developed. 5) I don’t know how you feel but 50% cure rate is unacceptable. 6) Over a million new cases discovered due to enormous blood donations following 911. 7) It’s time for a concerted effort, similar to AIDS research, is started. With several million deaths expected it’s time for action. – Corey, Falls Church, VA "Nico" <thera…@skynet.be> wrote in message
news:3c25ce52$0$10332$ba620e4c@news.skynet.be… – Hide quoted text — Show quoted text -> Hallo, > This info and figures are interesting…. can you give the source of all > this please? Thanks. > Best Regards, > Nico. > "JFH" <GoldDiscov…@webtv.net> schreef in bericht > news:8064-3C254E2A-453@storefull-283.iap.bryant.webtv.net… > ADVERSE REACTIONS > Nearly all study patients in clinical trials experienced one or more > adverse events. In the PEG monotherapy trial the incidence of serious > adverse events was similar (about 12%) in all treatment groups. In the > PEG-Intron/REBETOL combination trial the incidence of serious adverse > events was 17% in the PEG-Intron/REBETOL groups compared to 14% in the > INTRON A/REBETOL group. > In many but not all cases, adverse events resolved after dose reduction > or discontinuation of therapy. Some patients experienced ongoing or new > serious adverse events during the 6-month follow-up period. In the > PEG-Intron/REBETOL trial 13 patients experienced life-threatening > psychiatric events (suicidal ideation or attempt) and one patient > accomplished suicide. > There have been five patient deaths which occurred in clinical trials: > one suicide in a patient receiving PEG-Intron monotherapy and one > suicide in a patient receiving PEG-Intron/REBETOL combination therapy; > two deaths among patients receiving INTRON A monotherapy (1 > murder/suicide and 1 sudden death) and one patient death in the INTRON > A/REBETOL group (motor vehicle accident). > Overall 10-14% of patients receiving PEG-Intron, alone or in combination > with REBETOL, discontinued therapy compared with 6% treated with INTRON > A alone and 13% treated with INTRON A in combination with REBETOL. The > most common reasons for discontinuation of therapy were related to > psychiatric, systemic (e.g. fatigue, headache), or gastrointestinal > adverse events. > In the combination therapy trial, dose reductions due to adverse > reactions occurred in 42% of patients receiving PEG-Intron (1.5 >
